Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 7, 1999, Pages 865-868

  Sieg, A ^a,c   Sellinger, M ^c   Schlauch, D ^c   Horner M ^c   Fuchs, W ^b  

^a Practice for Gastroenterology   (Germany)

^b Takeda Pharma GmbH   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; UREASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEPTIC ULCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; PEPTIC ULCER; PROSPECTIVE STUDIES; PROTON PUMPS; TREATMENT OUTCOME;

EID: 0033039618     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00540.x     Document Type: Article

References (38)

1. Tytgat GNY. Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-68.
2. Labenz J, Börsch G. Klinik und Diagnostik der Helicobacter-pylori-Infektion. Dtsch Med Wschr 1994; 119: 633-6
3. Wotherspoon AC, Oritz Hidalgo C, Falzon MR, Isaacson G. Helicobacter pylori-associated gastritis and primary B cell gastric lymphoma. Lancet 1991; 338: 1175-6.
4. Bayerdörffer E, Neubauer A, Eidt S, et al. Double-blind treatment of early gastric MALT-lymphoma patients by Helicobacter pylori eradication. Gastroenterology 1994; 106: A370 (Abstract).
5. Correa P. Human gastric carcinogenesis. A multistep and multifactorial process. Cancer Res 1992; 87: 1635-40.
6. Logan RPH. Helicobacter pylori and gastric cancer. Lancet 1994; 344: 1078-9.
7. IARC. International Agency for Research in Cancer. Schistosomas, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994: 61.
8. Bazzoli FRM, Zagari S, Fossi P, et al. Short-term low dose triple therapy for eradication of Helicobacter pylori. Euro J Gastroenterol Hepatol 1994; 6: 773-7.
9. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. The MACH 1 study: optimal one-week treatment of H. pylori defined? Gut 1995; 37(Suppl. 1): A15 (Abstract).
10. Caspary WF, Arnold R, Bayerdörffer E, et al. Diagnostik und Therapie der Helicobacter pylori-Infektion. Leitlinien der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen. Z Gastroenterol 1996; 34: 392-401.
11. Burette A, Glupczynski Y, De Prez C, Combez A. Lansoprazole plus roxithromycin and metronidazole for eradication of H. pylori: Results of a single-blind pilot study. Acta Gastroenterol Belgica 1993; 131: 53 (Abstract).
12. Costa F, Amato G, Belcari C, et al. Treatment of Helicobacter pylori infection with different doses of clarithromycin combined with amoxicillin and lansoprazole. Gastroenterology 1997; 112: A 2166 (Abstract).
13. Eisold H. Abheilung von Ulcera duodeni und ventriculi sowie Eradikation von Helicobacter pylori unter Routinebedingungen einer gastroenterologischen Praxis. Verdauungskrankheiten 1996; 4: 133-5.
14. Fennerty B, Bianchi T, Rose R, Pilmer B, Kidd S, Siepman N. Triple therapy with lansoprazole, clarithromycin, and amoxicillin is highly effective in the eradication of Helicobacter pylori infection. Gastroenterology 1997; 112: A 2198 (Abstract).
15. Jaup BH, Norrby A. Comparison of two low dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection. Gastroenterology 1995; 108: A123 (Abstract).
16. Lamouliatte H, Courier A, Mion F, et al. Triple therapy with roxithromycin-amoxicillin and lansoprazole for Helicobacter pylori eradication: Results of an open multicenter study. Gastroenterology 1996; 110: A 1231 (Abstract).
17. Moayyedi P, Langworthy H, Tompkins DS, Mapstone N, Chalmers DM, Axon ATR. The optimum 5-day therapy against Helicobacter pylori. Gastroenterology 1997; 112: A 2196 (Abstract).
18. Spinzi GC, Colombo E, Bortoli A, et al. Lansoprazole vs omeprazole: one week triple therapy in peptic ulcer (preliminary results). Gastroenterology 1997; 112: A 2195 (Abstract).
19. Adamek RJ, Szymanski S, Pfaffenbach B, Opferkuch W, Ricken D, Wegener M. Kurzzeit-Tripel-Therapie mit Pantoprazol, Clarithromycin und Metronidazol zur Heilung der Helicobacter-pylori- Infektion. Dtsch Med Wschr 1995; 120: 358-60.
20. Labenz J, Peitz U, Tillenburg B, Becker T, Börsch G, Stolte M. Kurzzeit-Tripel-Therapie mit Pantoprazol, Clarithromycin und Metronidazol zur Eradikation von Helicobacter pylori. Leber Magen Darm 1995; 25: 122-7.
21. Witzel L, Leder K. Cure of Helicobacter pylori in duodenal ulcer disease with triple therapy consisting of pantoprazole, clarithromycin and metronidazole. Gastroenterology 1997; 112: A 2209 (Abstract).
22. Moayyedi P, Sahay P, Tompkins DS, Axon ATR. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7: 835-40.
23. Müllhaupt B, Flückinger Th, Fröhli P, Engelhart G, Hürlimann R. One-week low dose triple therapies with lansoprasole or omeprazole are equally effective for H. pylori eradication and ulcer healing. Gastroenterology 1996; 110: A1241 (Abstract).
24. Harris AW, Pryce DI, Gabe SM, et al. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 1005-8.
25. Sito E, Konturek Ch, Bielanski W. One-week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. J Physiol Pharmacol 1996; 4: 221-8.
26. Axon ATR, Moayyedi P. Eradication of Helicobacter pylori: Omeprazole in combination with antibiotics. Scand J Gastroent 1996; 31(Suppl 215): 82-9.
27. Unge B, Berstad A. Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand J Gastroent 1996; 31(Suppl 220): 27-40.
28. Seelis REA, Dohmen W. Kurzzeit-Eradikation der Helicobacter pylori- Infektion über 6 Tage in der Kassenarztpraxis. Dtsch Med Wschr 1998; 123: 103-8.
29. O'Connor HJ, Mc Loughlin R, Kelly S, Laundon J, Cunnane K. Lansoprazole triple therapy for Helicobacter pylori - is 5 days enough? Aliment Pharmacol Ther 1998; 12: 273-6.
30. Pieramico O, Zanetti MV, Innerhofer M. Three-day and seven-day triple therapy with clarithromycin or azithromycin for cure of H. pylori infection. Gastroenterology 1998; 114: A287(Abstract).
31. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 383-8.
32. Di Mario F, Buda A, Dal Bò N, et al. Different lansoprazole (LA) dosages in H. pylori (Hp) eradication therapy: a prospective multicenter randomized study comparing 30 mg B.I.D. vs 15 mg B.I.D. Gastroenterology 1998; 114: A286(Abstract).
33. Lamouliatte H, Forestier S, Perie F. Lansoprazole (Lanso) 30 mg or 60 mg combined with two antibiotics (amoxicillin and clarythromycin) to eradicate Helicobacter pylori. Gastroenterology 1998; 114: A1128(Abstract).
34. Lamouliatte H, Cayla R. Helicobacter pylori eradication with a one-week triple therapy: Meta-analysls of French studies. Gastroenterology 1998; 114: A286(Abstract).
35. Dohmen W, Seelis R. Ethnische Unterschiede in Epidemiologie und Therapie der Helicobacter-pylori-Infektion. Verdauungskrankheiten 1998; 1: 10-4.
36. Bereswill S, Strobel S, Steinbrückner B, et al. Genotyping of the vacA gene in Helicobacter pylori strains isolated form ulcus patients in Germany. Gut 1996; 39(Suppl. 2): A87(Abstract).
37. Rudi J, Kolb C, Maiwald M, et al. Diversity of Helicobacter pylori vacA and cagA genes in relationship to vacA and CagA protein expression, catotoxin production, and associated diseases. J Clin Microbiol 1998; 36: 944-8.
38. Pounder RE, Ng D. The prevalence of Helicobacter pylori in different countries. Aliment Pharmacol Ther 1995; 9(Suppl. 2): 33-9.